Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clarient has announced that it will commercialize a novel breast cancer test, claimed to be the first molecular test available that is applicable to all stages of operable breast cancer, including lymph node-positive patients.
Subscribe to our email newsletter
The new offering, called Clarient Insight Dx breast cancer profile, will be sold by Clarient through an exclusive license agreement with Prediction Sciences.
The profile is a series of molecular assays that, when combined using Prediction Sciences’s proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy.
Ron Andrews, Clarient’s president and CEO, said: “This new agreement provides Clarient with an important addition to our breast cancer menu, a new molecular diagnostic test that we believe predicts the likelihood of disease recurrence and ultimately the benefit of chemotherapy for patients. Along with its significant value for the over 35,000 breast cancer patients we expect to test this year, Clarient’s Insight Dx breast cancer profile has the potential to deliver a significant economic opportunity for the company.”